Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment()

Seminars in Ophthalmology
Andre J WitkinAllen C Ho

Abstract

To describe visual and anatomical outcomes following bi-weekly intravitreal ranibizumab/bevacizumab injections in eyes with refractory neovascular age-related macular degeneration (AMD) and pigment epithelial detachment (PED). Retrospective, consecutive, interventional case series. Eighteen patients diagnosed with neovascular AMD that were refractory to anti-VEGF therapy and received alternating biweekly ranibizumab/bevacizumab injections were included. Patients with neovascular AMD and PED that were refractory to at least 11 monthly ranibizumab or bevacizumab injections were included in this study at a large, single retina practice. Following inclusion, patients received four bi-weekly alternating ranibizumab/bevacizumab intravitreal injections. After completing a course of four bi-weekly injections, patients were treated with variable regimens of intravitreal anti-vascular endothelial growth factor (VEGF) therapy. The primary outcomes of the study included change in visual acuity (VA) and central foveal thickness (CFT) at eight weeks follow-up. Study eyes had previously received a mean of 22 intravitreal anti-VEGF injections. At enrollment, mean VA was 20/95 and mean CFT was 455 µm. After four bi-weekly anti-VEGF injections, ...Continue Reading

Associated Clinical Trials

References

Oct 6, 2006·The New England Journal of Medicine·Philip J RosenfeldUNKNOWN MARINA Study Group
Oct 6, 2006·The New England Journal of Medicine·David M BrownUNKNOWN ANCHOR Study Group
Nov 6, 2010·Investigative Ophthalmology & Visual Science·Isabelle GolbazUrsula Margarethe Schmidt-Erfurth
Jul 8, 2011·The British Journal of Ophthalmology·Maria Salling Eghøj, Torben Lykke Sørensen
Jul 28, 2011·The British Journal of Ophthalmology·Julie L GasperiniSriniVas R Sadda
May 5, 2012·Ophthalmology·UNKNOWN Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupFrederick L Ferris
Mar 21, 2013·Ophthalmic Surgery, Lasers & Imaging Retina·Charles C WykoffUNKNOWN SAVE Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.